Company intelligence / Profile preview
Suzhou Junjing BioSciences
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Junjing BioSciences is an innovative biotechnology joint venture focused on developing small molecule therapeutics targeting critical unmet needs in oncology. Its lead assets are in early clinical development (Phase 1/2), with a focus on advanced solid tumors and EGFR-mutant non-small cell lung cancer. The company has received IND approvals from both Chinese and US regulators for its XPO1 inhibitor program.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Junshi BiosciencesMicroecology BiosciencesWigen Biomedicine Technology (for specific programs)Academic collaborations mentioned but not detailed
Beyond the preview
Go deeper on Suzhou Junjing BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Junjing BioSciences.